Ilaria Proserpio

Varese, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer.

Body mass index (BMI) influence on Cetuximab-induced antibody-dependent cellular cytotoxicity in advanced colon cancer.

Journal: Internal and emergency medicine
Published: May 12, 2022

Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future.

Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future.

Journal: Anti-cancer drugs
Published: April 30, 2021

Complete testicular remission after chemotherapy in a patient with advanced seminoma: is the testicle a real 'sanctuary'? A case report and review of the literature.

Complete testicular remission after chemotherapy in a patient with advanced seminoma: is the testicle a real 'sanctuary'? A case report and review of the literature.

Journal: Anti-cancer drugs
Published: February 17, 2021

Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial.

Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial.

Journal: Cancers
Published: July 09, 2020

Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients.

Homcology: home chemotherapy delivery in a simultaneous care project for frail advanced cancer patients.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Published: March 19, 2020

Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.

Metabolic tumour volume and response to therapy in diffuse large B-cell lymphoma.

Journal: Hematological oncology
Published: March 24, 2019

Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study.

Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study.

Journal: Tumori
Published: March 13, 2019

Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-center experience.

Baseline PET as prognostic index in diffuse large B-cell lymphoma and grade IIIb follicular lymphoma: a retrospective study of a single-center experience.

Journal: The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...
Published: February 21, 2019

Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.

Primary extranodal diffuse large B-cell lymphomas: Many sites, many entities? Clinico-pathological, immunohistochemical and cytogenetic study of 106 cases.

Journal: Cancer genetics
Published: April 17, 2018

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study.

Journal: Targeted oncology
Published: March 28, 2018

Early colorectal cancer: diagnosis, treatment and survivorship care.

Early colorectal cancer: diagnosis, treatment and survivorship care.

Journal: Critical reviews in oncology/hematology
Published: October 06, 2017

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD).

Journal: Oncotarget
Published: August 06, 2015
Showing 1-12 of 18

Last Updated: 09/26/2026